Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head

Raturi, Vijay P.; Hojo, Hidehiro; Hotta, Kenji; Baba, Hiromi; Takahashi, Ryo; Rachi, Toshiya; Nakamura, Naoki; Zenda, Sadamoto; Motegi, Atsushi; Tachibana, Hidenobu; Ariji, Takaki; Motegi, Kana; Nakamura, Masaki; Okumura, Masayuki; Hirano, Yasuhiro; Akimoto, Tetsuo

doi:10.1186/s13014-020-01592-6

Table 3 Target volumes and OARs physical dosimetric parameters and comparative analysis between IMRT and ro-IMPT plans

From: Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head

Dosimetric Parameters	IMRT ((Mean ± SD)	ro-IMPT (Mean ± SD)	P-value IMRT vs. ro-IMPT
CTV coverage
CTV HI	0.04 ± 0.01	0.07 ± 0.01	0.004*
CTV CN	0.43 ± 0.03	0.58 ± 0.05	0.004*
Stomach
V55GyE	2.3 ± 1.0%	1.0 ± 0.9%	0.01*
V50GyE in cc	9.8 ± 4.9 cc	5.5 ± 4.6 cc	0.01*
V50GyE	4.0 ± 2.1%	2.3 ± 2.0%	0.01*
V45GyE	5.8 ± 3.2%	3.5 ± 3.1%	0.01*
V40GyE	7.8 ± 4.7%	5.9 ± 3.7%	0.01*
V30GyE	13.8 ± 9.2%	7.5 ± 5.6%	0.007*
V20GyE	28.7 ± 15.9%	11.1 ± 7.6%	0.004*
V10GyE	44.7 ± 18.0%	17.3 ± 12.0%	0.004*
D_0.1cc	56.4 ± 8.9 GyE	56.1 ± 8.3 GyE	0.44
Duodenum
V55GyE	1.8 ± 2.0%	1.2 ± 0.7%	0.36
V50GyE	7.5 ± 6.7%	3.6 ± 2.4%	0.11
V40GyE	13.7 ± 11.8%	11.4 ± 6.5%	0.16
V30GyE	22.7 ± 12.4%	22.9 ± 11.0%	0.73
V25GyE	29.5 ± 13.6%	30.5 ± 13.3%	0.09
V20GyE	39.4 ± 15.5%	39.4 ± 16.8%	0.49
V10GyE	62.8 ± 21.3%	56.5 ± 22.3%	0.003*
D_0.1cc	56.5 ± 5.6 GyE	55.3 ± 6.4 GyE	0.17
D_1cc	49.9 ± 7.1 GyE	49.5 ± 8.1 GyE	0.42
Small Bowel
V54GyE	1.2 ± 1.4%	0.5 ± 0.8%	0.02*
V50GyE	2.2 ± 2.5%	1.2 ± 2.0%	0.02*
V45GyE	3.5 ± 4.2%	2.1 ± 3.5%	0.02*
V40GyE	5.7 ± 6.2%	2.9 ± 4.7%	0.01*
V30GyE	19.3 ± 17.0%	5.1 ± 6.9%	0.004*
V20GyE	40.5 ± 19.6%	9.1 ± 9.3%	0.003*
V10GyE	57.9 ± 15.1%	17.9 ± 12.5%	0.004*
D_0.1cc	54.8 ± 7.9GyE	51.0 ± 10.9GyE	0.057
StoDuo
V55GyE	2.3 ± 1.2%	0.9 ± 0.8%	0.004*
V50GyE in cc	12.9 ± 5.6 cc	7.91 ± 4.4 cc	0.007*
V50GyE	4.5 ± 2.4%	2.5 ± 1.9%	0.01*
V40GyE	8.7 ± 4.6%	5.9 ± 3.7%	0.02*
V30GyE	15.2 ± 8.3%	10.1 ± 5.6%	0.03*
V20GyE	30.6 ± 13.5%	15.9 ± 7.8%	0.01*
V10GyE	48.0 ± 15.0%	23.9 ± 12.7%	0.004*
Kidneys
Mean dose (GyE)	6.01 ± 1.16 GyE	9.82 ± 2.80 GyE	0.004*
V23GyE	0.04 ± 0.07%	6.6 ± 6.7%	0.02*
Liver
Mean dose (GyE)	6.53 ± 3.2 GyE	5.64 ± 2.5 GyE	0.09
V35GyE	3.0 ± 2.2%	1.8 ± 1.2%	0.02*
V30GyE	4.2 ± 3.0%	2.6 ± 1.6%	0.03*
Spinal Cord
D_0.1cc	20.8 ± 1.9 GyE	7.27 ± 4.3 GyE	0.004*

Abbreviation: IMRT Intensity-modulated radiotherapy, ro-IMPT Robust Intensity-modulated proton therapy, CTV Clinical target volume, CN Conformation number, HI Homogeneity index, GyE Gray equivalent, cc cubic centimeter, V_(X)% percentage volume of OAR at or above “X” GyE, D_(X)cc GyE dose of OAR to “X” cc volume, SD Standard deviation
*Significant (P < 0.05)

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com

Radiation Oncology

Contact us